PHENYLPROPANOLAMINE INCREASES PLASMA CAFFEINE LEVELS

被引:21
作者
LAKE, CR
ROSENBERG, DB
GALLANT, S
ZALOGA, G
CHERNOW, B
机构
[1] WALTER REED ARMY MED CTR,F EDWARD HEBERT SCH MED,DEPT PSYCHIAT,WASHINGTON,DC 20307
[2] WALTER REED ARMY MED CTR,F EDWARD HEBERT SCH MED,DEPT MED PSYCHOL,WASHINGTON,DC 20307
[3] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT ANESTHESIA CRIT CARE MED,WINSTON SALEM,NC 27103
[4] HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02114
关键词
D O I
10.1038/clpt.1990.93
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of the widely consumed drugs caffeine and phenylpropanolamine are mediated through activation of the central and sympathetic nervous systems. Severe, life-threatening, and occasionally fatal hypertensive reactions have been reported after their combined use. This study examined the possible pharmacokinetic interaction of phenylpropanolamine and caffeine. Sixteen normal subjects received combinations of caffeine, phenylpropanolamine, and placebo. In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (±SEM) peak plasma caffeine concentration of 8.0 ± 2.2 μg/ml was significantly greater than after 400 mg caffeine alone (2.1 ± 0.3 μg/ml; t[24] = 2.4; p < 0.01). Physical side effects were more frequent after the phenylpropanolamine-caffeine combination than after either drug alone or after placebo. Greater increases in both systolic and diastolic blood pressures occurred after the combination than after either drug alone. Because caffeine levels can be increased greatly when certain other drugs are coconsumed, these data indicate that phenylpropanolamine may enhance absorption or inhibit elimination of caffeine and may explain increased side effects reported after their combined use. © 1990.
引用
收藏
页码:675 / 685
页数:11
相关论文
共 42 条
  • [1] ALTSCHULER S, 1982, INT J OBESITY, V6, P549
  • [2] MASSIVE CATECHOLAMINE RELEASE FROM CAFFEINE POISONING
    BENOWITZ, NL
    OSTERLOH, J
    GOLDSCHLAGER, N
    KAYSEN, G
    POND, S
    FORHAN, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 248 (09): : 1097 - 1098
  • [3] INHIBITION BY IDROCILAMIDE OF THE DISPOSITION OF CAFFEINE
    BRAZIER, JL
    DESCOTES, J
    LERY, N
    OLLAGNIER, M
    EVREUX, JC
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (01) : 37 - 43
  • [4] CHARNEY DS, 1985, ARCH GEN PSYCHIAT, V42, P233
  • [5] THE HEALTH CONSEQUENCES OF CAFFEINE
    CURATOLO, PW
    ROBERTSON, D
    [J]. ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) : 641 - 653
  • [6] MULTIPLE RANGE AND MULTIPLE F TESTS
    DUNCAN, DB
    [J]. BIOMETRICS, 1955, 11 (01) : 1 - 42
  • [7] DURETT LR, 1980, J NEUROSCI RES, V5, P587
  • [8] Gibaldi M., 1982, PHARMACOKINETICS, P445
  • [9] GREDEN JF, 1985, PHENYLPROPANOLAMINE, P165
  • [10] IMPROVED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF CAFFEINE AND ITS N-DEMETHYLATED METABOLITES IN PLASMA USING SOLID-PHASE EXTRACTION
    HARTLEY, R
    SMITH, IJ
    COOKMAN, JR
    [J]. JOURNAL OF CHROMATOGRAPHY, 1985, 342 (01): : 105 - 117